scout
|Videos|June 3, 2017

Efficacy Results for LOXO-101 in TRK Fusion Cancers

David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME